FDA Beats PMDA and EMA on Oncology Approvals - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
FDA Beats PMDA and EMA on Oncology Approvals

Source: Applied Clinical Trials

As first reported by Alec Gaffney of the news arm of the Regulatory Affairs Professional Society, the FDA hands down beats other regulatory authorities in approving oncology drugs.

In his article, Gaffney reports on FDA Commissioner’s Margaret Hamburg, MD, blog on achievements at the FDA. The oncology approvals were only one highlight from a report issued by the Centre for Innovation in Regulatory Science. In that report, CIRS found that the median approval times for anti-cancer beats median approval times for anti-cancer drugs in days was 450 for the EMA, 365 for the PMDA and 240 for the FDA.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here